ArticleNutrition, metabolism, and cardiovascular diseases : NMCD2020
Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19.
Article in Nutrition, metabolism, and cardiovascular diseases : NMCD, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 9 syntheses or guidelines pooled it, 85 citations in OpenAlex.
- Identification of Parameters Representative of Immune Dysfunction in Patients with Severe and Fatal COVID-19 Infection: a Systematic Review and Meta-analysis.Clinical reviews in allergy & immunology · 2023Pooled it
- The accuracy of machine learning approaches using non-image data for the prediction of COVID-19: A meta-analysis.International journal of medical informatics · 2022Pooled it
- Cardiovascular diseases burden in COVID-19: Systematic review and meta-analysis.The American journal of emergency medicine · 2021Pooled it
- Association of body mass index (BMI) with critical COVID-19 and in-hospital mortality: A dose-response meta-analysis.Metabolism: clinical and experimental · 2021Pooled it
- Hypertension is a clinically important risk factor for critical illness and mortality in COVID-19: A meta-analysis.Nutrition, metabolism, and cardiovascular diseases : NMCD · 2021Pooled it
- Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID-19 patients: A meta-regression and decision tree analysis.Journal of medical virology · 2020Pooled it
- Ferritin in the coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.Journal of clinical laboratory analysis · 2020Pooled it
- Pooled it
- Impact of obesity on hospitalizations and mortality, due to COVID-19: A systematic review.Obesity research & clinical practicePooled it
- Predicting COVID-19 Mortality Risk Among Cardiovascular Disease Patients Using Artificial Intelligence Algorithms: A Retrospective Study on Clinical Data.Health science reports · 2026Article
- Factors associated with an unfavorable outcome according to age in patients with COVID-19 admitted to intensive care in mainland France during the first three periods of the pandemic: a nationwide cohort study.Frontiers in medicine · 2026Article
- A cross-sectional, retrospective study analyzing the impact of COVID-19 on surgical mortality in Johannesburg, South Africa.Annals of medicine and surgery (2012) · 2025Article
- Assessing the impact of comorbidities on disease severity in COVID-19 patients requires consideration of age.Medicine · 2025Observational
- Phenotypic switch of vascular smooth muscle cells in COVID-19: Role of cholesterol, calcium, and phosphate.Journal of cellular physiology · 2024Review
- Investigation of Serum Endocan Levels in SARS-CoV-2 Patients.International journal of molecular sciences · 2024Article
- Phenome-wide association study and precision medicine of cardiovascular diseases in the post-COVID-19 era.Acta pharmacologica Sinica · 2023Review
- Article
- Hyperparameter optimization for cardiovascular disease data-driven prognostic system.Visual computing for industry, biomedicine, and art · 2023Article
- COVID-19 and coronary artery disease; A systematic review and meta-analysis.New microbes and new infections · 2023Review
- Epidemiological Features and Outcomes of COVID-19 in Patients With and Without Cardiovascular Disease.Archives of Iranian medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimA novel coronavirus severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) caused pneumonia, Coronavirus Disease 2019 (COVID-19), broke out in Wuhan, China in December 2019, and spread all over the world. Patients with COVID-19 showed huge differences in the hospital stay, progression, and prognosis. As reported, the comorbidities may play an important role in COVID-19. Here, we aim to address the role of cardiovascular disease (CVD) in the progression and prognosis of COVID-19. METHODS AND
resultsEighty-three confirmed COVID-19 patients were divided into CVD (n = 42) and non-CVD (n = 41) group according to their medical history. Medical records including demographic data, medical history, clinical characteristics, laboratory examinations, chest computed tomography (CT), and treatment measures were collected, analyzed, and compared between the two groups. COVID-19 patients with CVD showed (1) more severe pathological changes in the lungs, (2) elevated injury-related enzymes including α-hydroxybutyrate dehydrogenase (HDBH), lactic dehydrogenase (LDH), γ-glutamyltransferase (GGT), creatine kinase (CK), and alanine aminotransferase (ALT), (3) significantly increased uncontrolled inflammation related markers, such as c-reactive protein (CRP), interleukin (IL)-6, serum ferritin, erythrocyte sedimentation rate (ESR), and serum amyloid A (SAA), (4) serious hypercoagulable status reflected by increased D-dimer and serum fibrinogen (FIB), and (5) higher mortality, compared to COVID-19 patients without CVD.
conclusionsOur data indicated that CVD is a strong risk factor for rapid progression and bad prognosis of COVID-19. More intensive medical care should be applied to patients with CVD to prevent rapid deterioration of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.